221 related articles for article (PubMed ID: 9313205)
1. Zidovudine therapy, CD4+ and CD8+ counts are associated with a longer survival following AIDS onset.
Fiala M; Swartz J; Teklehaimanot S; Kermani V; Funnye AS; Sayre JW; Gornbein JA
Lymphology; 1997 Sep; 30(3):128-36. PubMed ID: 9313205
[TBL] [Abstract][Full Text] [Related]
2. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
3. CD8+ lymphocyte counts and the risk of death in advanced HIV infection.
Schlumpberger JM; Wolde-Tsadik G; Yao JF; Hara J
J Fam Pract; 1994 Jan; 38(1):33-8. PubMed ID: 8289049
[TBL] [Abstract][Full Text] [Related]
4. Early versus deferred zidovudine monotherapy: impact on AIDS-free time and survival in the multicenter AIDS cohort study.
Detels R; Muñoz A; Peng Y; Graham N; Mellors J; Phair J
Antivir Ther; 1997 Jan; 2(1):21-9. PubMed ID: 11322263
[TBL] [Abstract][Full Text] [Related]
5. Logarithmic relationship of the CD4 count to survival in patients with human immunodeficiency virus infection.
Nightingale SD; Jockusch JD; Haslund I; Cal SX; Peterson DM; Loss SD
Arch Intern Med; 1993 Jun; 153(11):1313-8. PubMed ID: 8099477
[TBL] [Abstract][Full Text] [Related]
6. Survival of patients receiving zidovudine before or after AIDS diagnosis: results of a German multicenter study. German AIDS Study Group.
Clin Investig; 1994 Jan; 72(2):111-6. PubMed ID: 8186655
[TBL] [Abstract][Full Text] [Related]
7. Disease progression in HIV-infected patients treated with stavudine vs. zidovudine.
Justice AC; Stein DS; Fusco GP; Sherrill BH; Fusco JS; Danehower SC; Becker SL; Hansen NI; Graham NM;
J Clin Epidemiol; 2004 Jan; 57(1):89-97. PubMed ID: 15019015
[TBL] [Abstract][Full Text] [Related]
8. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
[TBL] [Abstract][Full Text] [Related]
9. Modelling progression of CD4-lymphocyte count and its relationship to survival time.
De Gruttola V; Tu XM
Biometrics; 1994 Dec; 50(4):1003-14. PubMed ID: 7786983
[TBL] [Abstract][Full Text] [Related]
10. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
[TBL] [Abstract][Full Text] [Related]
11. Gender-specific differences in the natural history, clinical features, and socioeconomic status of HIV-infected patients: experience of a treatment centre in Vienna.
Armbruster C; Kriwanek S; Vorbach H
Wien Klin Wochenschr; 2000 Sep; 112(17):754-60. PubMed ID: 11042904
[TBL] [Abstract][Full Text] [Related]
12. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
[TBL] [Abstract][Full Text] [Related]
13. [Survival of patients with zidovudine resistant HIV].
Gøtzsche PC; Nielsen C; Gerstoft J; Nielsen CM; Vestergaard BF
Ugeskr Laeger; 1994 Jan; 156(2):185-6. PubMed ID: 7905217
[TBL] [Abstract][Full Text] [Related]
14. Characterization of reactivation of cytomegalovirus retinitis in patients healed after treatment with highly active antiretroviral therapy.
Song MK; Karavellas MP; MacDonald JC; Plummer DJ; Freeman WR
Retina; 2000; 20(2):151-5. PubMed ID: 10783947
[TBL] [Abstract][Full Text] [Related]
15. The prognosis of CMV retinitis among patients with AIDS in Serbia.
Dujić M; Jevtović Dj; Salemović D; Ranin J; Brmbolić B; Djurković-Djaković O
Biomed Pharmacother; 2008 Sep; 62(7):443-7. PubMed ID: 18243635
[TBL] [Abstract][Full Text] [Related]
16. Markers of response to zidovudine monotherapy among treated HIV seroconverters. Italian Seroconversion Study.
Rezza G; Galai N; Pezzotti P; Vlahov D; Graham NM; Viale P; Angarano G
Antivir Ther; 1997 Jul; 2(3):167-74. PubMed ID: 11322271
[TBL] [Abstract][Full Text] [Related]
17. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales MA; Sirera G; Clotet B
Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus retinitis under combination therapy with zidovudine and dideoxycytidine in advanced human immunodeficiency virus infection.
Kaulen P; Pham DT; Baranowski E; Wollensak J
Ger J Ophthalmol; 1993 Nov; 2(6):412-5. PubMed ID: 8312826
[TBL] [Abstract][Full Text] [Related]
19. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.
Braitstein P; Zala C; Yip B; Brinkhof MW; Moore D; Hogg RS; Montaner JS
J Infect Dis; 2006 Jan; 193(2):259-68. PubMed ID: 16362890
[TBL] [Abstract][Full Text] [Related]
20. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
